Cargando…

Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential

BACKGROUND: Nanobodies, named as VHHs (variable domain of heavy chain of HCAb [heavy-chain antibodies]), are derived from heavy-chain-only antibodies that circulate in sera of camelids. Their exceptional physicochemical properties, possibility of humanization, and unique antigen recognition properti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Yuan, Li, Jialu, Zhu, Xuejun, Tang, Xiaowen, Bao, Yangyi, Sun, Xiang, Huang, Yuhui, Tian, Fang, Liu, Xiaomei, Yang, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357075/ https://www.ncbi.nlm.nih.gov/pubmed/28331319 http://dx.doi.org/10.2147/IJN.S127575

Ejemplares similares

Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells
por: Tang, Jinle, et al.
Publicado: (2016)

Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment
por: Narbona, Javier, et al.
Publicado: (2023)

Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody
por: Chen, Ying, et al.
Publicado: (2017)

Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin
por: Flavell, D J, et al.
Publicado: (2001)

CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin
por: Ma, Jingbo, et al.
Publicado: (2022)

Novel recombinant immunotoxin of EGFR specific nanobody fused with cucurmosin, construction and antitumor efficiency in vitro
por: Deng, Cuimin, et al.
Publicado: (2017)

Development of Recombinant Immunotoxins for Hairy Cell Leukemia
por: Kreitman, Robert J., et al.
Publicado: (2020)

B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease.
por: Vooijs, W. C., et al.
Publicado: (1997)

Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect
por: Heiat, Mohammad, et al.
Publicado: (2021)

Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
por: Flavell, D. J., et al.
Publicado: (1997)

Nanobody: a promising toolkit for molecular imaging and disease therapy
por: Bao, Guangfa, et al.
Publicado: (2021)

Identification of Nanobodies against the Acute Myeloid Leukemia Marker CD33
por: Romão, Ema, et al.
Publicado: (2020)

A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer
por: Kollmorgen, Gwendlyn, et al.
Publicado: (2017)

Immunotoxin Therapy for Lung Cancer
por: Xie, Li-Yi, et al.
Publicado: (2017)

Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia
por: Deng, Manman, et al.
Publicado: (2018)

A Comparison of the Anti-Tumor Effects of a Chimeric versus Murine Anti-CD19 Immunotoxins on Human B Cell Lymphoma and Pre-B Acute Lymphoblastic Leukemia Cell Lines
por: Tsai, Lydia K., et al.
Publicado: (2011)

Immunotoxins: experimental design
por: Dall, P, et al.
Publicado: (2001)

Immunotoxins: The Role of the Toxin (†)
por: Antignani, Antonella, et al.
Publicado: (2013)

Countering immunotoxin immunogenicity
por: Flavell, David J
Publicado: (2016)

E2A-PBX1 exhibited a promising prognosis in pediatric acute lymphoblastic leukemia treated with the CCLG-ALL2008 protocol
por: Hu, Yixin, et al.
Publicado: (2016)

DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia
por: Sexauer, Amy N., et al.
Publicado: (2023)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
por: Bokori-Brown, Monika, et al.
Publicado: (2018)

Pediatric Acute Lymphoblastic Leukemia Patients Exhibit Distinctive Alterations in the Gut Microbiota
por: Liu, Xiaoming, et al.
Publicado: (2020)

Synthesis of an Anti-CD7 Recombinant Immunotoxin Based on PE24 in CHO and E. coli Cell-Free Systems
por: Krebs, Simon K., et al.
Publicado: (2022)

Treatment of solid tumors with immunotoxins
por: Messmer, Davorka, et al.
Publicado: (2005)

Bouganin, an Attractive Weapon for Immunotoxins
por: Bortolotti, Massimo, et al.
Publicado: (2018)

CD3-immunotoxin mediated depletion of T cells in lymphoid tissues of rhesus macaques
por: Wang, Lan, et al.
Publicado: (2023)

Production and Evaluation of an Avian IgY Immunotoxin against CD133+ for Treatment of Carcinogenic Stem Cells in Malignant Glioma: IgY Immunotoxin for the Treatment of Glioblastoma
por: Chavez-Cortez, Elda-Georgina, et al.
Publicado: (2019)

The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment
por: Rudin, Shoshana, et al.
Publicado: (2017)

Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia
por: Bárcenas-López, Diego Alberto, et al.
Publicado: (2020)

Diphtheria toxin‐based anti‐human CD19 immunotoxin for targeting human CD19(+) tumors
por: Zheng, Qian, et al.
Publicado: (2017)

Identification and characterization of blocking nanobodies against human CD70: Identification and characterization of blocking nanobodies
por: Zhang, Xin, et al.
Publicado: (2022)

Novel Isoquinolinamine and Isoindoloquinazolinone Compounds Exhibit Antiproliferative Activity in Acute Lymphoblastic Leukemia Cells
por: Roolf, Catrin, et al.
Publicado: (2019)

Camels’ biological fluids contained nanobodies: promising avenue in cancer therapy
por: Al-Numair, Nouf S., et al.
Publicado: (2022)

Cytotoxins and immunotoxins for cancer therapy : clinical applications /
Publicado: (2005)

CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia
por: Jiang, Zhiwu, et al.
Publicado: (2016)

Macrophage-Targeted Therapy: CD64-Based Immunotoxins for Treatment of Chronic Inflammatory Diseases
por: Hristodorov, Dmitrij, et al.
Publicado: (2012)

A novel immunotoxin reveals a new role for CD321 in endothelial cells
por: Fukuhara, Takeshi, et al.
Publicado: (2017)

Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity
por: Ataee, Mohammad Hossein, et al.
Publicado: (2022)

Prognostic Role of CD200 in Acute Lymphoblastic Leukemia Patients
por: Khalil, Mohamed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r6rhea8k7msaro1ll2o8db54f1